Genetic Therapy Review
Genetic Therapy Notes
Page 1: Overview
Speaker: Maria Pala
Affiliation: University of Huddersfield
Date: 23/01/2025
Focus on inspiring global professionals in genetic therapy through innovative research, collaboration with healthcare systems, and advancing educational methodologies in the field. Involvement in workshops and conferences to share cutting-edge developments and practices in genetic therapy.
Page 2: Key Terminology
Altered Chromosome Numbers: Refers to numerical aberrations, such as aneuploidy or polyploidy, that can lead to genetic disorders like Down syndrome and Turner syndrome.
Altered Chromosome Structures: Also known as structural aberrations, these involve deletions, duplications, inversions, or translocations that can contribute to various genetic disorders, including cancers and congenital anomalies.
Procedures for Prenatal Screening: Consists of ultrasound imaging to assess fetal development, biochemical testing to identify markers for abnormalities, chromosomal analysis via karyotyping, and DNA testing including NIPT to screen for specific genetic conditions with high accuracy.
Non-Invasive Prenatal Testing (NIPT): Advances in NIPT have significantly reduced the need for invasive prenatal procedures, facilitating safer screening for conditions such as trisomy 21 (Down syndrome) with minimal risk to the fetus.
Invasive Prenatal Sampling: Involves techniques like amniocentesis and chorionic villus sampling (CVS) that provide larger amounts of fetal DNA for comprehensive diagnostic tests, allowing for early detection of genetic disorders.
Page 5: Definitions and Distinctions
Treatment of Genetic Diseases: Informed by disease history, family genetics, and traditional therapy approaches, focusing on stabilizing the patient’s condition and enhancing quality of life.
Genetic Treatment of Diseases: Involves innovative technologies such as CRISPR for genetic modifications, RNA interference, and the development of personalized medicine based on genomic profiling to directly address the underlying genetic causes.
Page 6: General Treatment Avenues
Prevention: Tailored strategies to limit substrates, including diet modifications and lifestyle changes to reduce disease risk linked to genetic factors.
Treatment of Harmful Effects: Techniques include removing toxic substances from the body and inhibiting harmful metabolic pathways through targeted therapeutic interventions.
Compensation for Deficiencies: Approaches involve augmenting bodily functions via supplementation of hormones or enzymes, and providing necessary factors for normal bodily functioning.
Focus on Inborn Errors of Metabolism: Understanding specific metabolic pathways helps design treatment strategies for various disorders, such as phenylketonuria (PKU) and galactosemia.
Page 7: Steps in Genetic Treatment
Identification of novel drug targets based on genetic pathways.
Use of genetic technology for drug production, including biologics and recombinant proteins.
Development of personalized treatments to minimize adverse effects through pharmacogenomics and individual response profiles.
Genetic modification techniques for treatment (Gene Therapy), including designing vector systems.
Implementation of Cell Therapies aimed at restoring normal function in diseased or defective tissues without invasive procedures.
Page 8: Interdisciplinary Approach
Incorporation of Biochemistry, Genetics, and Cell Biology to enhance understanding of disease pathways and drug action.
Key activities include:
Cloning genes and monitoring gene activity, assessing gene expression levels in various biological contexts.
Identifying and culturing affected cell types to study disease mechanisms and evaluate potential therapeutic interventions.
Page 9: Drug Targets Identification
Overview of Gaucher Disease:
A rare lipid storage disorder due to the accumulation of glucocerebroside in cells, leading to severe physiological complications.
Drug Targets: Biological agents focused on substrate reduction therapies to lower glucocerebroside levels and alleviate symptoms.
Page 10: Designing Effective Therapies
The success of effective biologic drugs relies on a deep understanding of cellular pathways and existing drug targets.
Emphasis on developing robust disease models to refine drug testing and optimize therapeutic strategies.
Page 11: Cystic Fibrosis Overview
CFTR Gene Mutations: More than 1,700 mutations identified in the CFTR gene can lead to the manifestation of cystic fibrosis, affecting respiratory and digestive systems.
Drug targets focus on the cystic fibrosis transmembrane conductance regulator (CFTR) to improve chloride ion transport.
Ongoing clinical trials of therapies such as ivacaftor and lumacaftor targeting specific mutations, emphasizing precision medicine.
Page 12: Mutations and Molecular Therapies
A detailed understanding of molecular pathophysiology drives the development of targeted therapies that address specific mutations.
Example: The p.G551D mutation in CFTR and corresponding treatments utilizing potentiators to enhance protein function in mutant CFTR.
Page 13: Overview of Therapeutic Antibodies
The use of monoclonal antibodies plays a pivotal role in treating autoimmune conditions and specific cancers, providing targeted therapeutic options.
Different types include fully humanized, chimeric antibodies, along with various marketed products such as Humira for Crohn’s disease and Rituxan for certain lymphomas.
Page 14: Personalized Medicine
The growing importance of pharmacogenomics in customizing drug responses based on individual genetic profiles.
Understanding drug-receptor interactions, including common drugs like beta-blockers, and variations in receptor gene variants such as ADRB polymorphisms that can influence drug effectiveness.
Page 15: Treatment Strategies Overview
A. Treatment of Genetic Deficiency: Aims at restoration of normal function through supply of functional genes, gene editing, or cell therapy options.
B. Treatment of Disorders with Harmful Effects: Involves innovative techniques to inhibit or correct negative functions such as enzyme replacement therapy or gene silencing.
C. Preventive Treatment: Focused on addressing genetic susceptibility to mitigate disease onset through lifestyle changes, screening, and prophylactic therapies.
Page 16: Gene Therapy Introduction
Germline vs Somatic Gene Therapy:
Germline therapy: Currently faces ethical considerations and is generally banned in many regions due to the inheritability of changes; potential for unintended consequences on future generations.
Somatic therapy: Involves modification of target cells for purposes such as augmentation, silencing, or repair without passing on genetic changes to offspring.
Page 17: Gene Delivery Challenges
Gene delivery poses critical challenges in effective gene therapy implementation.
Approaches are tailored for specific tissues and involve both ex vivo techniques (culturing cells outside the body for modification) and in vivo strategies (directly delivering therapies into the body).
Page 18: Gene Transfer Methods
Transfection (non-viral): Utilizing plasmids is a common method, though it often suffers from low efficiency in gene delivery.
Transduction (viral): Involves integrating DNA into the host genome, which is advantageous for stable expression but carries risks such as insertional mutagenesis.
Page 19: Non-Viral Gene Delivery
Various non-viral vectors such as liposomes show a safer profile compared to viruses, though this often comes at the cost of lower long-term effectiveness in gene transfer.
A comprehensive comparison based on delivery mechanisms assesses short-term versus long-term efficacy and safety profiles.
Page 20: Viral Vectors Overview
An overview of viral types includes various classes of DNA and RNA viruses that each have unique mechanisms affecting gene delivery strategies tailored to specific therapeutic objectives.
Page 21: Construction of Recombinant Viruses
The advanced process of developing retroviral vectors for gene therapy involves sophisticated techniques including gene insertion into the viral genomes, ensuring specificity and efficiency in therapeutic gene delivery.
Page 22: Gene Delivery via Viral Vectors
The role of various viral vectors such as adenovirus, adeno-associated virus, and lentivirus in facilitating durable gene transfer, ensuring the stability and expression of therapeutic genes over time.
Page 23: Safety Issues in Viral Gene Delivery
Critical considerations during the development of viral vectors encompass immunogenicity and the risk of oncogene activation associated with retroviral vectors, necessitating thorough preclinical assessment.
Page 24: Selective Targeting for Gene Delivery
Utilizing specific surface markers to enhance selectivity and targeting accuracy in delivering genes via viral vectors, aiming to minimize off-target effects and enhance therapeutic outcomes.
Page 25: Disease Models in Gene Therapy Testing
Highlighting the significance of developing suitable disease models for effective drug development and the ethical considerations surrounding animal testing, adhering to the 3R principles (Replacement, Reduction, Refinement) to ensure humane practices.
Page 26: Clinical Trials Phases
Overview of the clinical pathway, progressing from preclinical testing through to Phase IV trials, with a particular emphasis on their applicability to rare diseases where therapeutic options are limited.
Page 27: Gene Therapy Applications in Clinical Trials
Mapping the distribution of gene therapy applications across various medical conditions, focusing on success rates in clinical trials, and potential future implications for mainstream treatments.
Page 28: Future Directions
Exploration of emerging gene therapy outcomes, including milestones in severe combined immunodeficiency (SCID) treatments and innovative strategies aimed at vision rejuvenation, emphasizing the need for continued research and development.
Page 29: Recap of Learning Objectives
In conclusion, the content covered emphasizes the biological treatment of metabolic disorders, the evolving strategies for gene therapy, and the critical methods of gene delivery tailored to specific patient needs and clinical contexts.